Breaking News, Trials & Filings

BMS’ Belatacept BLA Accepted for Review

Bristol-Myers Squibb’s BLA for belatacept has been accepted for filing and review by the FDA.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb’s BLA for belatacept has been accepted for filing and review by the FDA. The drug is currently in Phase III development for use in kidney transplantation. “Belatacept has the potential to address significant unmet medical needs of transplant patients,” said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president, R&D, Bristol-Myers Squibb. “We are pleased the FDA has accepted our submission and we look forward to continuing to work...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters